Meeting
2020 ASCO Virtual Scientific Program
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy (CCRT) for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082).
Authors
Akiko Furusawa
Department of Gynecology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
Akiko Furusawa , Munetaka Takekuma , Tomoka Usami , Eiji Kondo , Shin Nishio , Koji Nishino , Yuichiro Miyamoto , Ryoichi Yoshimura , Miho Watanabe , Mikio Mikami , Takayuki Enomoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
041190042
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS6094)
DOI
10.1200/JCO.2020.38.15_suppl.TPS6094
Abstract #
TPS6094
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer-A phase III, randomized, double-blind, multicenter study.
First Author: Bradley J. Monk
Poster
2022 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2022 ASCO Annual Meeting
Randomized controlled trial of the efficacy of lymph node dissection on stage IIICr of cervical cancer (CQGOG0103).
First Author: Misi He
Poster
2021 ASCO Annual Meeting
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
First Author: Andreas Rimner